Iovance Biotherapeutics, Inc. - Common Stock - Çeyreklik Finansal İstatistikler (NASDAQ:IOVA)

Financials

İşletme faaliyetlerinden elde edilen nakit -73.3 M-103.69 M-67.45 M-78.7 M-52.56 M-72.07 M -270.79 M Yatırım faaliyetlerinden elde edilen nakit 23.68 M15.87 M13.84 M17.01 M775 K11.39 M 43.02 M Finansman faaliyetlerinden elde edilen nakit 2.31 M143.31 M13.23 M88.06 M56.17 M94.33 M 251.79 M Serbest nakit akışı -73.3 M-103.69 M-74.91 M-89.55 M-61.88 M-78.68 M -305.02 M

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte therapies against cancer.

IOVA

Financials

Iovance Biotherapeutics, Inc. - Common Stock

Haberler

IBRX Stock Outlook After Q1 Results and a New FDA Review

ImmunityBio: Anktiva Explained and What Comes Next

AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?

Biyoteknoloji hisseleri arasında açığa satışta en fazla artış Intellia’da - Baird

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates

Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates

Undercovered Stocks: Western Digital, SAP, Toast And More

Pacira (PCRX) Q1 Earnings Miss Estimates

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Regeneron (REGN) Surpasses Q1 Earnings and Revenue Estimates